• Cat-intel
  • MedIntelliX
  • Consulting
  • Resources
  • About Us
  • News
  • Careers
  • Contact Us
  • Login
    • Request Free Sample ×
    ReportInfographic

    Kindly complete the form below to receive a free sample of this Report

    Leading companies partner with us for data-driven Insights

    clients tt-cursor

    Psoriasis Drug Market

    ID: MRFR/CnM/39241-HCR
    111 Pages
    Chitranshi Jaiswal
    September 2025

    Psoriasis Drug Market Research Report: By Medication Type (Topical Treatments, Systemic Therapies, Biologics), By Route of Administration (Topical, Oral, Injectable), By Disease Severity (Mild to Moderate, Moderate to Severe, Severe) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Forecast to 2034.

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Psoriasis Drug Market Research Report - Global Forecast by 2034 Infographic
    Purchase Options
    $ 4,950.0
    $ 5,950.0
    $ 7,250.0
    Compare License
    Table of Contents

    Psoriasis Drug Market Summary

    The Global Psoriasis Drug Market is projected to grow significantly over the next decade.

    Key Market Trends & Highlights

    Psoriasis Drug Key Trends and Highlights

    • The market valuation is expected to increase from 31.9 USD Billion in 2024 to 62.6 USD Billion by 2035.
    • The compound annual growth rate (CAGR) for the period from 2025 to 2035 is estimated at 6.33%.
    • This growth trajectory indicates a robust demand for innovative psoriasis treatments in the coming years.
    • Growing adoption of biologics due to their effectiveness is a major market driver.

    Market Size & Forecast

    2024 Market Size 31.9 (USD Billion)
    2035 Market Size 62.6 (USD Billion)
    CAGR (2025-2035) 6.33%

    Major Players

    AbbVie, Novartis, Eli Lilly and Company, Johnson Johnson, Celgene Corporation, Sanofi, Amgen, AstraZeneca, Sun Pharmaceutical Industries, Merck Co., LEO Pharma, Pfizer, GlaxoSmithKline, Mylan, Bristol Myers Squibb

    Psoriasis Drug Market Trends

    The rising prevalence of psoriasis, increasing awareness of effective treatments, and advancements in drug development are key drivers of the psoriasis drug market. Continuous improvements in treatment options, including the emergence of novel therapies such as biologics and targeted therapies, have expanded the therapeutic arsenal.Opportunities for growth in the market lie in the development of personalized medicine approaches, focusing on tailoring treatments to individual patient needs. Additionally, there is scope for innovation in combination therapies, leveraging synergies between different mechanisms of action to improve treatment efficacy and reduce side effects.

    Collaboration between pharmaceutical companies, academic institutions, and patient advocacy groups is fostering research and development efforts.Recent trends in the psoriasis drug market include a shift towards more targeted and effective therapies, with a focus on reducing systemic exposure and improving patient outcomes. Additionally, there is a growing interest in non-invasive and patient-centric approaches, such as self-injectable biologics and topical formulations, to enhance patient convenience and adherence to treatment regimens. These trends are shaping the future direction of the psoriasis drug market, highlighting the importance of continued investment in research and innovation to address unmet medical needs and improve patient care.

    The ongoing evolution of treatment options for psoriasis suggests a shift towards more personalized therapies, reflecting a growing understanding of the disease's complex pathophysiology.

    U.S. National Library of Medicine

    Psoriasis Drug Market Drivers

    Market Growth Projections

    The Global Psoriasis Drug Market Industry is poised for substantial growth, with projections indicating a market value of 31.9 USD Billion in 2024 and an anticipated increase to 62.6 USD Billion by 2035. This growth trajectory reflects a compound annual growth rate of 6.33% from 2025 to 2035. The increasing prevalence of psoriasis, advancements in treatment options, and rising healthcare expenditures are key factors contributing to this upward trend. As the market evolves, it is expected to attract significant investment, fostering innovation and improving patient outcomes.

    Rising Prevalence of Psoriasis

    The increasing prevalence of psoriasis globally serves as a primary driver for the Global Psoriasis Drug Market Industry. Current estimates indicate that psoriasis affects approximately 2-3% of the global population, translating to millions of individuals seeking effective treatment options. This growing patient population is likely to escalate demand for innovative therapies, thereby contributing to the market's expansion. As awareness of the condition rises, more patients are likely to seek medical advice, further propelling the need for effective psoriasis drugs. Consequently, the Global Psoriasis Drug Market Industry is projected to reach 31.9 USD Billion in 2024, reflecting the urgent need for effective treatment solutions.

    Increased Healthcare Expenditure

    The rise in global healthcare expenditure is a critical factor influencing the Global Psoriasis Drug Market Industry. Governments and private sectors are increasingly investing in healthcare, leading to improved access to treatment for psoriasis patients. This trend is particularly evident in developed regions, where healthcare systems are prioritizing dermatological conditions. Enhanced funding allows for the development and distribution of advanced psoriasis therapies, thereby meeting the growing demand. As healthcare expenditure continues to rise, it is anticipated that the Global Psoriasis Drug Market Industry will benefit significantly, with a projected compound annual growth rate of 6.33% from 2025 to 2035.

    Regulatory Support for New Drug Approvals

    Regulatory support for the approval of new psoriasis drugs is an essential driver for the Global Psoriasis Drug Market Industry. Regulatory agencies are increasingly streamlining the approval process for innovative therapies, thereby facilitating quicker access to new treatments for patients. This supportive environment encourages pharmaceutical companies to invest in research and development, leading to a more diverse range of treatment options. As new drugs receive approval and enter the market, competition increases, potentially lowering costs and improving accessibility for patients. This dynamic is likely to enhance the overall growth of the Global Psoriasis Drug Market Industry.

    Growing Awareness and Education Initiatives

    Growing awareness and education initiatives surrounding psoriasis are pivotal in driving the Global Psoriasis Drug Market Industry. Various organizations and healthcare providers are actively promoting understanding of the condition, its symptoms, and available treatment options. These initiatives aim to reduce stigma and encourage individuals to seek medical help. As awareness increases, more patients are likely to be diagnosed and treated, leading to a higher demand for psoriasis drugs. This trend is expected to contribute positively to the market's growth trajectory, as the industry adapts to meet the needs of an informed patient population.

    Advancements in Biologics and Targeted Therapies

    Recent advancements in biologics and targeted therapies represent a significant driver for the Global Psoriasis Drug Market Industry. These innovative treatments, which specifically target the underlying mechanisms of psoriasis, have shown promising efficacy and safety profiles. For instance, biologics such as IL-17 inhibitors and IL-23 inhibitors have transformed the treatment landscape, offering patients improved outcomes. The introduction of these therapies not only enhances patient quality of life but also stimulates market growth as healthcare providers increasingly adopt these advanced treatment modalities. As a result, the Global Psoriasis Drug Market Industry is expected to witness substantial growth, with projections indicating a market value of 62.6 USD Billion by 2035.

    Market Segment Insights

    Psoriasis Drug Market Segment Insights

    Psoriasis Drug Market Medication Type Insights

    The psoriasis drugs market, according to the medication type, is classified into topical treatment, systemic therapies and biologics. Topical treatment, which typically involves the use of ointments, creams, and lotions applied directly to the skin, is considered the major contributor, generating more than 45% of the revenue as of 2023. They are known for treating the area, relatively safe and well-tolerated. Nonetheless, efficacy may be questionable for severe psoriasis. Systemic therapies usually consist of pills or injections that treat moderate or severe psoriasis.They work by suppressing the overactive immune system and reducing inflammation.

    In recent years, systemic therapies have demonstrated significant growth and are expected to continue due to the gradual and constant development of new and more efficient methods. Biologics are a relatively new therapy for treating psoriasis. These drugs are derived from living sources and are generally much more efficient in treatment. Biologics act on specific immune system proteins.

    The biologics type of the market is forecasted to be the fastest-growing, with an increasing number of available, newer drugs.The psoriasis drugs market is an extremely competitive one, with a number of major pharmaceutical giants investing heavily and competing in the acquisition and development of better drugs. The largest major players are AbbVie, Novartis, Eli Lilly and Co., and Johnson Johnson. The dropIndexPsoriasis market is expected to be extremely competitive in the coming years. AbbVie, Novartis, J, and Eli Lily are some of the major players in the market.

    The companies are continuously investing in acquiring other, smaller companies or developing new drugs on their own.

    Source: Primary Research, Secondary Research, Market Research Future Database and Analyst Review

    Psoriasis Drug Market Route of Administration Insights

    The Psoriasis Drug Market is segmented by Route of Administration into Topical, Oral and Injectable. In 2023, a topical segment of the market dominated the market and is expected to dominate in the forecast period as well. The topical segment holds an approximately 55% value share of the market. The usage of topical formulations has the least side effects, like oral administration, but it is easy to use because of the availability of creams, ointments, and gel formulations.

    The Oral segment is expected to be the fastest-growing segment in the forecast period.The usage of oral therapies for moderate-to-severe psoriasis is growing to systemically treat the condition and offer better control of symptoms and long-term benefits. The Injectable segment is expected to grow at a medium pace, mainly because the approvals of new injectable biologics for the treatment of psoriasis are increasing.

    Psoriasis Drug Market Disease Severity Insights

    The Psoriasis Drug Market is segmented into mild to moderate, moderate to severe, and severe disease severity. The severe segment held the largest market share in 2023, accounting for over 40% of the Psoriasis Drug Market revenue. The moderate to severe segment is expected to grow at the highest CAGR during the forecast period due to the increasing prevalence of moderate to severe psoriasis and the availability of new and effective treatments. The mild to moderate segment is expected to grow at a steady pace due to the increasing awareness of psoriasis and the availability of over-the-counter treatments.

    Regional Insights

    The Psoriasis Drug Market is segmented into North America, Europe, APAC, South America and MEA. North America dominates the market with a revenue of USD 12.4 billion in 2023 and is expected to reach USD 20.7 billion by 2032, growing at a CAGR of 6.5%. Europe is the second-largest market, with a revenue of USD 9.8 billion in 2023 and is expected to reach USD 16.3 billion by 2032, growing at a CAGR of 6.7%.

    APAC is the fastest-growing region, with a revenue of USD 6.2 billion in 2023 and is expected to reach USD 11.4 billion by 2032, growing at a CAGR of 7.5%.South America and MEA are expected to grow at a CAGR of 6.0% and 5.8%, respectively, over the forecast period. The growth in the regional markets is attributed to the increasing prevalence of psoriasis, rising disposable income, and growing awareness of advanced treatment options.

    Source: Primary Research, Secondary Research, Market Research Future Database and Analyst Review

    Key Players and Competitive Insights

    The Psoriasis Drug Market competitive environment is one of the most flexible and dynamic, having numerous players, both well-established and emerging, competing for the share of the market. Hence, current prominent companies in the Psoriasis Drug Market include AbbVie, Novartis, Eli Lilly and Company, Janssen Pharmaceuticals and Celgene Corporation, among others. The market for Psoriasis Drugs is becoming increasingly competitive as leading companies focus on the development of innovative and effective drugs to meet the growing needs of the patient population.

    Leading companies also spend an ever-growing amount of time and resources on research and development to ensure access to a wider selection of medication and collaborate in various ways to enhance the industry, as it enables companies to pool resources to address the existing unmet needs in the health sector. Moreover, mergers and acquisitions are an excellent way for pharmaceutical companies to increase their presence in certain segments or geographic locations or strengthen their positions in the market, specifically, in this case, Psoriasis Drug Market.AbbVie is one of the leaders in the Psoriasis Drug Market.

    The company is one of the globally known biopharmaceutical companies with a focus on developing potentially promising and viable solutions to treat different diseases, including psoriasis. Humira is known to be a highly effective medication to treat Psoriasis, and it has become one of the most commonly used drugs for moderate to severe psoriasis. In addition, Humira has a positive effect on joints, which is particularly significant as psoriatic arthritis remains one of the most challenging forms of the disease to treat.

    AbbVie has also made commendable progress in immunology and successfully brought new solutions, recently launching Skyrizi, which is a next-generation biologic medication for patients with psoriasis with high efficacy. As far as Janssen Pharmaceuticals, a subsidiary of Johnson Johnson, is concerned, the company has also made a great contribution to the development of the Psoriasis Drug Market. Being active since the mid-2000s and currently offers a range of psoriasis medications such as Stelara, an average Psoriasis medication, and Tremfya, one of the clearly visible next-generation medications with even higher efficacy as they are more target-oriented in comparison to their predecessors.

    In addition, Janssen Pharmaceuticals also made great progress in researching the issue of psoriasis, discovering promising molecules with high efficacy and good safety profiles of several such molecules. Further, Janssen Pharmaceuticals has excellent access to the commercial market, and its patient- and operator-centered approach has ensured a positive position in the Psoriasis Drug Market.

    Key Companies in the Psoriasis Drug Market market include

    Industry Developments

    • Q2 2024: MoonLake Immunotherapeutics Announces Positive Results from Phase 3 Trial of Sonelokimab in Psoriasis MoonLake Immunotherapeutics reported positive top-line results from its Phase 3 trial of Sonelokimab, a novel biologic for moderate-to-severe plaque psoriasis, paving the way for regulatory submission.
    • Q2 2024: AnaptysBio Announces FDA Acceptance of Imsidolimab Biologics License Application for Generalized Pustular Psoriasis AnaptysBio announced that the FDA has accepted its Biologics License Application for Imsidolimab, a monoclonal antibody targeting IL-36, for the treatment of generalized pustular psoriasis.
    • Q2 2024: Takeda and Nimbus Announce Strategic Partnership to Develop TAK-279 for Psoriasis Takeda and Nimbus Lakshmi entered a strategic partnership to co-develop TAK-279, a TYK2 inhibitor, for the treatment of moderate-to-severe psoriasis.
    • Q3 2024: UCB Receives FDA Approval for BIMZELX (bimekizumab) for Moderate to Severe Plaque Psoriasis UCB announced that the FDA has approved BIMZELX (bimekizumab), a dual IL-17A and IL-17F inhibitor, for the treatment of adults with moderate to severe plaque psoriasis.
    • Q3 2024: Dermavant Secures $200 Million Series C Funding to Advance VTAMA Cream for Psoriasis Dermavant Sciences raised $200 million in Series C funding to support the commercialization and further development of VTAMA (tapinarof) cream for plaque psoriasis.
    • Q4 2024: MoonLake Immunotherapeutics Submits Marketing Authorization Application for Sonelokimab to EMA MoonLake Immunotherapeutics submitted a Marketing Authorization Application to the European Medicines Agency for Sonelokimab, targeting moderate-to-severe plaque psoriasis.
    • Q4 2024: AbbVie Announces FDA Approval of SKYRIZI for Expanded Psoriasis Indication AbbVie received FDA approval for an expanded indication of SKYRIZI (risankizumab-rzaa) to include treatment of adults with erythrodermic psoriasis.
    • Q1 2025: Novartis Launches Cosentyx Autoinjector Device for Psoriasis Patients in the US Novartis launched a new autoinjector device for Cosentyx, designed to improve ease of use for patients with moderate-to-severe plaque psoriasis in the United States.
    • Q1 2025: Amgen Announces Opening of New Biologics Manufacturing Facility to Support Psoriasis Drug Production Amgen opened a new biologics manufacturing facility in North Carolina to increase production capacity for its psoriasis drug portfolio.
    • Q2 2025: Eli Lilly Receives FDA Approval for Mirikizumab for Moderate to Severe Plaque Psoriasis Eli Lilly announced FDA approval of Mirikizumab, an IL-23p19 antagonist, for the treatment of adults with moderate to severe plaque psoriasis.
    • Q2 2025: Bristol Myers Squibb Announces European Commission Approval of Sotyktu for Psoriasis Bristol Myers Squibb received European Commission approval for Sotyktu (deucravacitinib), a TYK2 inhibitor, for the treatment of moderate-to-severe plaque psoriasis.
    • Q3 2025: Janssen Announces FDA Approval of Tremfya for Pediatric Plaque Psoriasis Janssen, a Johnson & Johnson company, announced FDA approval of Tremfya (guselkumab) for the treatment of pediatric patients with moderate-to-severe plaque psoriasis.

    Future Outlook

    Psoriasis Drug Market Future Outlook

    The Global Psoriasis Drug Market is projected to grow at a 6.33% CAGR from 2024 to 2035, driven by increasing prevalence, innovative therapies, and rising healthcare expenditures.

    New opportunities lie in:

    • Develop personalized biologics targeting specific psoriasis subtypes.
    • Expand telemedicine services for remote patient management and consultations.
    • Invest in combination therapies to enhance treatment efficacy and patient adherence.

    By 2035, the market is expected to be robust, reflecting significant advancements in treatment options and patient care.

    Market Segmentation

    Psoriasis Drug Market Regional Outlook

    • North America
    • Europe
    • South America
    • Asia Pacific
    • Middle East and Africa

    Psoriasis Drug Market Medication Type Outlook

    • Topical Treatments
    • Systemic Therapies
    • Biologics

    Psoriasis Drug Market Disease Severity Outlook

    • Mild to Moderate
    • Moderate to Severe
    • Severe

    Psoriasis Drug Market Route of Administration Outlook

    • Topical
    • Oral
    • Injectable

    Report Scope

    Report Attribute/Metric Details
    Market Size 2022 28.24(USD Billion)
    Market Size 2023 30.03(USD Billion)
    Market Size 2032 52.1(USD Billion)
    Compound Annual Growth Rate (CAGR) 6.32% (2024 - 2032)
    Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
    Base Year 2023
    Market Forecast Period 2024 - 2032
    Historical Data 2019 - 2023
    Market Forecast Units USD Billion
    Key Companies Profiled Novartis, AbbVie, Celgene, Sanofi, Amgen, AstraZeneca, Eli Lilly and Company, Johnson Johnson, Sun Pharmaceutical Industries, Merck Co., LEO Pharma, Pfizer, GlaxoSmithKline, Mylan, BristolMyers Squibb
    Segments Covered Medication Type, Route of Administration, Disease Severity, Regional
    Key Market Opportunities Targeted therapies Biosimilars Combination therapies Topical therapies Digital health solutions
    Key Market Dynamics Increasing incidence of psoriasis Growing adoption of biologics Advancements in gene therapy Government initiatives for psoriasis awareness Rising demand for personalized medicine
    Countries Covered North America, Europe, APAC, South America, MEA

    Market Highlights

    Author
    Chitranshi Jaiswal
    Research Analyst Level I

    In her 3 years of experience in the market research field, she has handled critical cross-domain projects. She has an in-depth knowledge of market estimation & analysis, problem-solving, primary as well as secondary research, and team management.She holds an engineering degree and is an MBA professional from a well-known university, capable of evaluating the market and competitive conditions. An exceptional strategist with excellent communication skills and a passion for delivering cutting-edge & practical insights for the market. Proficient in multi-tasking, and can successfully deal with competing demands, while maintaining complete confidentiality. Generated business through active client and project development, networking, and high-quality responses. Her knowledge and skills have helped in making solid business decisions, securing funding from investors, and avoiding business failures.

    Get In Touch
    Leave a Comment

    FAQs

    What is the current market size of the Psoriasis Drug Market?

    The psoriasis drug market was valued at 30.03 billion USD in 2023 and is projected to reach 52.1 billion USD by 2032, exhibiting a CAGR of 6.32% during the forecast period.

    What are the major segments of the Psoriasis Drug Market?

    The market is segmented based on drug class, route of administration, and region. By drug class, the market is segmented into biologics, small molecules, and topical therapies. By route of administration, the market is segmented into oral, injectable, and topical. By region, the market is segmented into North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa.

    What are the key factors driving the growth of the Psoriasis Drug Market?

    The increasing prevalence of psoriasis, raising awareness about the disease and treatment options, and the development of new and effective drugs are the key factors driving the growth of the psoriasis drug market.

    What are the major challenges faced by the Psoriasis Drug Market?

    The high cost of biologics, the side effects associated with some drugs, and the lack of access to treatment in developing countries are the major challenges faced by the psoriasis drug market.

    Who are the key players in the Psoriasis Drug Market?

    Some of the key players in the psoriasis drug market include AbbVie, Amgen, Celgene, Eli Lilly, Janssen, Merck, Novartis, Pfizer and Sanofi.

    What are the major trends in the Psoriasis Drug Market?

    The increasing adoption of biologics, the development of biosimilars, and the focus on personalized medicine are the major trends in the psoriasis drug market.

    What is the future outlook of the Psoriasis Drug Market?

    The psoriasis drug market is expected to continue to grow in the future, driven by the increasing prevalence of psoriasis and the development of new and effective drugs.

    What are the regional variations in the Psoriasis Drug Market?

    North America is the largest market for psoriasis drugs, followed by Europe and Asia-Pacific. The market in Asia-Pacific is expected to grow at the highest rate during the forecast period.

    What are the unmet needs in the Psoriasis Drug Market?

    There is a need for more effective and affordable drugs for psoriasis, as well as drugs that can target the underlying causes of the disease.

    What are the potential opportunities in the Psoriasis Drug Market?

    The increasing prevalence of psoriasis and the development of new and effective drugs represent potential opportunities for growth in the psoriasis drug market.

    1.     1. EXECUTIVE SUMMARY 
    2.         1.1. Market Overview 
    3.         1.2. Key Findings 
    4.         1.3. Market Segmentation 
    5.         1.4. Competitive Landscape 
    6.         1.5. Challenges and Opportunities 
    7.         1.6. Future Outlook 
    8.     2. MARKET INTRODUCTION 
    9.         2.1. Definition 
    10.         2.2. Scope of the study 
    11.             2.2.1. Research Objective 
    12.             2.2.2. Assumption 
    13.             2.2.3. Limitations 
    14.     3. RESEARCH METHODOLOGY 
    15.         3.1. Overview 
    16.         3.2. Data Mining 
    17.         3.3. Secondary Research 
    18.         3.4. Primary Research 
    19.             3.4.1. Primary Interviews and Information Gathering Process 
    20.             3.4.2. Breakdown of Primary Respondents 
    21.         3.5. Forecasting Model 
    22.         3.6. Market Size Estimation 
    23.             3.6.1. Bottom-Up Approach 
    24.             3.6.2. Top-Down Approach 
    25.         3.7. Data Triangulation 
    26.         3.8. Validation 
    27.     4. MARKET DYNAMICS 
    28.         4.1. Overview 
    29.         4.2. Drivers 
    30.         4.3. Restraints 
    31.         4.4. Opportunities 
    32.     5. MARKET FACTOR ANALYSIS 
    33.         5.1. Value chain Analysis 
    34.         5.2. Porter's Five Forces Analysis 
    35.             5.2.1. Bargaining Power of Suppliers 
    36.             5.2.2. Bargaining Power of Buyers 
    37.             5.2.3. Threat of New Entrants 
    38.             5.2.4. Threat of Substitutes 
    39.             5.2.5. Intensity of Rivalry 
    40.         5.3. COVID-19 Impact Analysis 
    41.             5.3.1. Market Impact Analysis 
    42.             5.3.2. Regional Impact 
    43.             5.3.3. Opportunity and Threat Analysis 
    44.     6. Psoriasis Drug Market, BY Medication Type (USD Billion) 
    45.         6.1. Topical Treatments 
    46.         6.2. Systemic Therapies 
    47.         6.3. Biologics 
    48.     7. Psoriasis Drug Market, BY Route of Administration (USD Billion) 
    49.         7.1. Topical 
    50.         7.2. Oral 
    51.         7.3. Injectable 
    52.     8. Psoriasis Drug Market, BY Disease Severity (USD Billion) 
    53.         8.1. Mild to Moderate 
    54.         8.2. Moderate to Severe 
    55.         8.3. Severe 
    56.     9. Psoriasis Drug Market, BY Regional (USD Billion) 
    57.         9.1. North America 
    58.             9.1.1. US 
    59.             9.1.2. Canada 
    60.         9.2. Europe 
    61.             9.2.1. Germany 
    62.             9.2.2. UK 
    63.             9.2.3. France 
    64.             9.2.4. Russia 
    65.             9.2.5. Italy 
    66.             9.2.6. Spain 
    67.             9.2.7. Rest of Europe 
    68.         9.3. APAC 
    69.             9.3.1. China 
    70.             9.3.2. India 
    71.             9.3.3. Japan 
    72.             9.3.4. South Korea 
    73.             9.3.5. Malaysia 
    74.             9.3.6. Thailand 
    75.             9.3.7. Indonesia 
    76.             9.3.8. Rest of APAC 
    77.         9.4. South America 
    78.             9.4.1. Brazil 
    79.             9.4.2. Mexico 
    80.             9.4.3. Argentina 
    81.             9.4.4. Rest of South America 
    82.         9.5. MEA 
    83.             9.5.1. GCC Countries 
    84.             9.5.2. South Africa 
    85.             9.5.3. Rest of MEA 
    86.     10. Competitive Landscape 
    87.         10.1. Overview 
    88.         10.2. Competitive Analysis 
    89.         10.3. Market share Analysis 
    90.         10.4. Major Growth Strategy in the Psoriasis Drug Market 
    91.         10.5. Competitive Benchmarking 
    92.         10.6. Leading Players in Terms of Number of Developments in the Psoriasis Drug Market 
    93.         10.7. Key developments and growth strategies 
    94.             10.7.1. New Product Launch/Service Deployment 
    95.             10.7.2. Merger & Acquisitions 
    96.             10.7.3. Joint Ventures 
    97.         10.8. Major Players Financial Matrix 
    98.             10.8.1. Sales and Operating Income 
    99.             10.8.2. Major Players R&D Expenditure. 2023 
    100.     11. Company Profiles 
    101.         11.1. Novartis 
    102.             11.1.1. Financial Overview 
    103.             11.1.2. Products Offered 
    104.             11.1.3. Key Developments 
    105.             11.1.4. SWOT Analysis 
    106.             11.1.5. Key Strategies 
    107.         11.2. AbbVie 
    108.             11.2.1. Financial Overview 
    109.             11.2.2. Products Offered 
    110.             11.2.3. Key Developments 
    111.             11.2.4. SWOT Analysis 
    112.             11.2.5. Key Strategies 
    113.         11.3. Celgene 
    114.             11.3.1. Financial Overview 
    115.             11.3.2. Products Offered 
    116.             11.3.3. Key Developments 
    117.             11.3.4. SWOT Analysis 
    118.             11.3.5. Key Strategies 
    119.         11.4. Sanofi 
    120.             11.4.1. Financial Overview 
    121.             11.4.2. Products Offered 
    122.             11.4.3. Key Developments 
    123.             11.4.4. SWOT Analysis 
    124.             11.4.5. Key Strategies 
    125.         11.5. Amgen 
    126.             11.5.1. Financial Overview 
    127.             11.5.2. Products Offered 
    128.             11.5.3. Key Developments 
    129.             11.5.4. SWOT Analysis 
    130.             11.5.5. Key Strategies 
    131.         11.6. AstraZeneca 
    132.             11.6.1. Financial Overview 
    133.             11.6.2. Products Offered 
    134.             11.6.3. Key Developments 
    135.             11.6.4. SWOT Analysis 
    136.             11.6.5. Key Strategies 
    137.         11.7. Eli Lilly and Company 
    138.             11.7.1. Financial Overview 
    139.             11.7.2. Products Offered 
    140.             11.7.3. Key Developments 
    141.             11.7.4. SWOT Analysis 
    142.             11.7.5. Key Strategies 
    143.         11.8. Johnson Johnson 
    144.             11.8.1. Financial Overview 
    145.             11.8.2. Products Offered 
    146.             11.8.3. Key Developments 
    147.             11.8.4. SWOT Analysis 
    148.             11.8.5. Key Strategies 
    149.         11.9. Sun Pharmaceutical Industries 
    150.             11.9.1. Financial Overview 
    151.             11.9.2. Products Offered 
    152.             11.9.3. Key Developments 
    153.             11.9.4. SWOT Analysis 
    154.             11.9.5. Key Strategies 
    155.         11.10. Merck Co. 
    156.             11.10.1. Financial Overview 
    157.             11.10.2. Products Offered 
    158.             11.10.3. Key Developments 
    159.             11.10.4. SWOT Analysis 
    160.             11.10.5. Key Strategies 
    161.         11.11. LEO Pharma 
    162.             11.11.1. Financial Overview 
    163.             11.11.2. Products Offered 
    164.             11.11.3. Key Developments 
    165.             11.11.4. SWOT Analysis 
    166.             11.11.5. Key Strategies 
    167.         11.12. Pfizer 
    168.             11.12.1. Financial Overview 
    169.             11.12.2. Products Offered 
    170.             11.12.3. Key Developments 
    171.             11.12.4. SWOT Analysis 
    172.             11.12.5. Key Strategies 
    173.         11.13. GlaxoSmithKline 
    174.             11.13.1. Financial Overview 
    175.             11.13.2. Products Offered 
    176.             11.13.3. Key Developments 
    177.             11.13.4. SWOT Analysis 
    178.             11.13.5. Key Strategies 
    179.         11.14. Mylan 
    180.             11.14.1. Financial Overview 
    181.             11.14.2. Products Offered 
    182.             11.14.3. Key Developments 
    183.             11.14.4. SWOT Analysis 
    184.             11.14.5. Key Strategies 
    185.         11.15. BristolMyers Squibb 
    186.             11.15.1. Financial Overview 
    187.             11.15.2. Products Offered 
    188.             11.15.3. Key Developments 
    189.             11.15.4. SWOT Analysis 
    190.             11.15.5. Key Strategies 
    191.     12. Appendix 
    192.         12.1. References 
    193.         12.2. Related Reports 
    194.     Table 1. LIST OF ASSUMPTIONS 
    195.     Table 2. North America Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY MEDICATION TYPE, 2019-2032 (USD Billions) 
    196.     Table 3. North America Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD Billions) 
    197.     Table 4. North America Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY DISEASE SEVERITY, 2019-2032 (USD Billions) 
    198.     Table 5. North America Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD Billions) 
    199.     Table 6. US Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY MEDICATION TYPE, 2019-2032 (USD Billions) 
    200.     Table 7. US Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD Billions) 
    201.     Table 8. US Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY DISEASE SEVERITY, 2019-2032 (USD Billions) 
    202.     Table 9. US Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD Billions) 
    203.     Table 10. Canada Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY MEDICATION TYPE, 2019-2032 (USD Billions) 
    204.     Table 11. Canada Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD Billions) 
    205.     Table 12. Canada Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY DISEASE SEVERITY, 2019-2032 (USD Billions) 
    206.     Table 13. Canada Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD Billions) 
    207.     Table 14. Europe Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY MEDICATION TYPE, 2019-2032 (USD Billions) 
    208.     Table 15. Europe Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD Billions) 
    209.     Table 16. Europe Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY DISEASE SEVERITY, 2019-2032 (USD Billions) 
    210.     Table 17. Europe Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD Billions) 
    211.     Table 18. Germany Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY MEDICATION TYPE, 2019-2032 (USD Billions) 
    212.     Table 19. Germany Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD Billions) 
    213.     Table 20. Germany Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY DISEASE SEVERITY, 2019-2032 (USD Billions) 
    214.     Table 21. Germany Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD Billions) 
    215.     Table 22. UK Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY MEDICATION TYPE, 2019-2032 (USD Billions) 
    216.     Table 23. UK Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD Billions) 
    217.     Table 24. UK Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY DISEASE SEVERITY, 2019-2032 (USD Billions) 
    218.     Table 25. UK Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD Billions) 
    219.     Table 26. France Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY MEDICATION TYPE, 2019-2032 (USD Billions) 
    220.     Table 27. France Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD Billions) 
    221.     Table 28. France Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY DISEASE SEVERITY, 2019-2032 (USD Billions) 
    222.     Table 29. France Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD Billions) 
    223.     Table 30. Russia Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY MEDICATION TYPE, 2019-2032 (USD Billions) 
    224.     Table 31. Russia Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD Billions) 
    225.     Table 32. Russia Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY DISEASE SEVERITY, 2019-2032 (USD Billions) 
    226.     Table 33. Russia Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD Billions) 
    227.     Table 34. Italy Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY MEDICATION TYPE, 2019-2032 (USD Billions) 
    228.     Table 35. Italy Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD Billions) 
    229.     Table 36. Italy Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY DISEASE SEVERITY, 2019-2032 (USD Billions) 
    230.     Table 37. Italy Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD Billions) 
    231.     Table 38. Spain Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY MEDICATION TYPE, 2019-2032 (USD Billions) 
    232.     Table 39. Spain Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD Billions) 
    233.     Table 40. Spain Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY DISEASE SEVERITY, 2019-2032 (USD Billions) 
    234.     Table 41. Spain Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD Billions) 
    235.     Table 42. Rest of Europe Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY MEDICATION TYPE, 2019-2032 (USD Billions) 
    236.     Table 43. Rest of Europe Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD Billions) 
    237.     Table 44. Rest of Europe Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY DISEASE SEVERITY, 2019-2032 (USD Billions) 
    238.     Table 45. Rest of Europe Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD Billions) 
    239.     Table 46. APAC Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY MEDICATION TYPE, 2019-2032 (USD Billions) 
    240.     Table 47. APAC Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD Billions) 
    241.     Table 48. APAC Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY DISEASE SEVERITY, 2019-2032 (USD Billions) 
    242.     Table 49. APAC Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD Billions) 
    243.     Table 50. China Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY MEDICATION TYPE, 2019-2032 (USD Billions) 
    244.     Table 51. China Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD Billions) 
    245.     Table 52. China Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY DISEASE SEVERITY, 2019-2032 (USD Billions) 
    246.     Table 53. China Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD Billions) 
    247.     Table 54. India Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY MEDICATION TYPE, 2019-2032 (USD Billions) 
    248.     Table 55. India Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD Billions) 
    249.     Table 56. India Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY DISEASE SEVERITY, 2019-2032 (USD Billions) 
    250.     Table 57. India Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD Billions) 
    251.     Table 58. Japan Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY MEDICATION TYPE, 2019-2032 (USD Billions) 
    252.     Table 59. Japan Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD Billions) 
    253.     Table 60. Japan Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY DISEASE SEVERITY, 2019-2032 (USD Billions) 
    254.     Table 61. Japan Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD Billions) 
    255.     Table 62. South Korea Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY MEDICATION TYPE, 2019-2032 (USD Billions) 
    256.     Table 63. South Korea Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD Billions) 
    257.     Table 64. South Korea Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY DISEASE SEVERITY, 2019-2032 (USD Billions) 
    258.     Table 65. South Korea Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD Billions) 
    259.     Table 66. Malaysia Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY MEDICATION TYPE, 2019-2032 (USD Billions) 
    260.     Table 67. Malaysia Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD Billions) 
    261.     Table 68. Malaysia Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY DISEASE SEVERITY, 2019-2032 (USD Billions) 
    262.     Table 69. Malaysia Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD Billions) 
    263.     Table 70. Thailand Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY MEDICATION TYPE, 2019-2032 (USD Billions) 
    264.     Table 71. Thailand Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD Billions) 
    265.     Table 72. Thailand Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY DISEASE SEVERITY, 2019-2032 (USD Billions) 
    266.     Table 73. Thailand Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD Billions) 
    267.     Table 74. Indonesia Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY MEDICATION TYPE, 2019-2032 (USD Billions) 
    268.     Table 75. Indonesia Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD Billions) 
    269.     Table 76. Indonesia Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY DISEASE SEVERITY, 2019-2032 (USD Billions) 
    270.     Table 77. Indonesia Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD Billions) 
    271.     Table 78. Rest of APAC Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY MEDICATION TYPE, 2019-2032 (USD Billions) 
    272.     Table 79. Rest of APAC Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD Billions) 
    273.     Table 80. Rest of APAC Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY DISEASE SEVERITY, 2019-2032 (USD Billions) 
    274.     Table 81. Rest of APAC Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD Billions) 
    275.     Table 82. South America Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY MEDICATION TYPE, 2019-2032 (USD Billions) 
    276.     Table 83. South America Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD Billions) 
    277.     Table 84. South America Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY DISEASE SEVERITY, 2019-2032 (USD Billions) 
    278.     Table 85. South America Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD Billions) 
    279.     Table 86. Brazil Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY MEDICATION TYPE, 2019-2032 (USD Billions) 
    280.     Table 87. Brazil Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD Billions) 
    281.     Table 88. Brazil Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY DISEASE SEVERITY, 2019-2032 (USD Billions) 
    282.     Table 89. Brazil Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD Billions) 
    283.     Table 90. Mexico Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY MEDICATION TYPE, 2019-2032 (USD Billions) 
    284.     Table 91. Mexico Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD Billions) 
    285.     Table 92. Mexico Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY DISEASE SEVERITY, 2019-2032 (USD Billions) 
    286.     Table 93. Mexico Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD Billions) 
    287.     Table 94. Argentina Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY MEDICATION TYPE, 2019-2032 (USD Billions) 
    288.     Table 95. Argentina Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD Billions) 
    289.     Table 96. Argentina Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY DISEASE SEVERITY, 2019-2032 (USD Billions) 
    290.     Table 97. Argentina Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD Billions) 
    291.     Table 98. Rest of South America Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY MEDICATION TYPE, 2019-2032 (USD Billions) 
    292.     Table 99. Rest of South America Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD Billions) 
    293.     Table 100. Rest of South America Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY DISEASE SEVERITY, 2019-2032 (USD Billions) 
    294.     Table 101. Rest of South America Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD Billions) 
    295.     Table 102. MEA Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY MEDICATION TYPE, 2019-2032 (USD Billions) 
    296.     Table 103. MEA Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD Billions) 
    297.     Table 104. MEA Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY DISEASE SEVERITY, 2019-2032 (USD Billions) 
    298.     Table 105. MEA Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD Billions) 
    299.     Table 106. GCC Countries Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY MEDICATION TYPE, 2019-2032 (USD Billions) 
    300.     Table 107. GCC Countries Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD Billions) 
    301.     Table 108. GCC Countries Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY DISEASE SEVERITY, 2019-2032 (USD Billions) 
    302.     Table 109. GCC Countries Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD Billions) 
    303.     Table 110. South Africa Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY MEDICATION TYPE, 2019-2032 (USD Billions) 
    304.     Table 111. South Africa Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD Billions) 
    305.     Table 112. South Africa Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY DISEASE SEVERITY, 2019-2032 (USD Billions) 
    306.     Table 113. South Africa Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD Billions) 
    307.     Table 114. Rest of MEA Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY MEDICATION TYPE, 2019-2032 (USD Billions) 
    308.     Table 115. Rest of MEA Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD Billions) 
    309.     Table 116. Rest of MEA Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY DISEASE SEVERITY, 2019-2032 (USD Billions) 
    310.     Table 117. Rest of MEA Psoriasis Drug Market SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD Billions) 
    311.     Table 118. PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL 
    312.     Table 119. ACQUISITION/PARTNERSHIP
    313.     Figure 1. MARKET SYNOPSIS 
    314.     Figure 2. NORTH AMERICA PSORIASIS DRUG MARKET ANALYSIS 
    315.     Figure 3. US PSORIASIS DRUG MARKET ANALYSIS BY MEDICATION TYPE 
    316.     Figure 4. US PSORIASIS DRUG MARKET ANALYSIS BY ROUTE OF ADMINISTRATION 
    317.     Figure 5. US PSORIASIS DRUG MARKET ANALYSIS BY DISEASE SEVERITY 
    318.     Figure 6. US PSORIASIS DRUG MARKET ANALYSIS BY REGIONAL 
    319.     Figure 7. CANADA PSORIASIS DRUG MARKET ANALYSIS BY MEDICATION TYPE 
    320.     Figure 8. CANADA PSORIASIS DRUG MARKET ANALYSIS BY ROUTE OF ADMINISTRATION 
    321.     Figure 9. CANADA PSORIASIS DRUG MARKET ANALYSIS BY DISEASE SEVERITY 
    322.     Figure 10. CANADA PSORIASIS DRUG MARKET ANALYSIS BY REGIONAL 
    323.     Figure 11. EUROPE PSORIASIS DRUG MARKET ANALYSIS 
    324.     Figure 12. GERMANY PSORIASIS DRUG MARKET ANALYSIS BY MEDICATION TYPE 
    325.     Figure 13. GERMANY PSORIASIS DRUG MARKET ANALYSIS BY ROUTE OF ADMINISTRATION 
    326.     Figure 14. GERMANY PSORIASIS DRUG MARKET ANALYSIS BY DISEASE SEVERITY 
    327.     Figure 15. GERMANY PSORIASIS DRUG MARKET ANALYSIS BY REGIONAL 
    328.     Figure 16. UK PSORIASIS DRUG MARKET ANALYSIS BY MEDICATION TYPE 
    329.     Figure 17. UK PSORIASIS DRUG MARKET ANALYSIS BY ROUTE OF ADMINISTRATION 
    330.     Figure 18. UK PSORIASIS DRUG MARKET ANALYSIS BY DISEASE SEVERITY 
    331.     Figure 19. UK PSORIASIS DRUG MARKET ANALYSIS BY REGIONAL 
    332.     Figure 20. FRANCE PSORIASIS DRUG MARKET ANALYSIS BY MEDICATION TYPE 
    333.     Figure 21. FRANCE PSORIASIS DRUG MARKET ANALYSIS BY ROUTE OF ADMINISTRATION 
    334.     Figure 22. FRANCE PSORIASIS DRUG MARKET ANALYSIS BY DISEASE SEVERITY 
    335.     Figure 23. FRANCE PSORIASIS DRUG MARKET ANALYSIS BY REGIONAL 
    336.     Figure 24. RUSSIA PSORIASIS DRUG MARKET ANALYSIS BY MEDICATION TYPE 
    337.     Figure 25. RUSSIA PSORIASIS DRUG MARKET ANALYSIS BY ROUTE OF ADMINISTRATION 
    338.     Figure 26. RUSSIA PSORIASIS DRUG MARKET ANALYSIS BY DISEASE SEVERITY 
    339.     Figure 27. RUSSIA PSORIASIS DRUG MARKET ANALYSIS BY REGIONAL 
    340.     Figure 28. ITALY PSORIASIS DRUG MARKET ANALYSIS BY MEDICATION TYPE 
    341.     Figure 29. ITALY PSORIASIS DRUG MARKET ANALYSIS BY ROUTE OF ADMINISTRATION 
    342.     Figure 30. ITALY PSORIASIS DRUG MARKET ANALYSIS BY DISEASE SEVERITY 
    343.     Figure 31. ITALY PSORIASIS DRUG MARKET ANALYSIS BY REGIONAL 
    344.     Figure 32. SPAIN PSORIASIS DRUG MARKET ANALYSIS BY MEDICATION TYPE 
    345.     Figure 33. SPAIN PSORIASIS DRUG MARKET ANALYSIS BY ROUTE OF ADMINISTRATION 
    346.     Figure 34. SPAIN PSORIASIS DRUG MARKET ANALYSIS BY DISEASE SEVERITY 
    347.     Figure 35. SPAIN PSORIASIS DRUG MARKET ANALYSIS BY REGIONAL 
    348.     Figure 36. REST OF EUROPE PSORIASIS DRUG MARKET ANALYSIS BY MEDICATION TYPE 
    349.     Figure 37. REST OF EUROPE PSORIASIS DRUG MARKET ANALYSIS BY ROUTE OF ADMINISTRATION 
    350.     Figure 38. REST OF EUROPE PSORIASIS DRUG MARKET ANALYSIS BY DISEASE SEVERITY 
    351.     Figure 39. REST OF EUROPE PSORIASIS DRUG MARKET ANALYSIS BY REGIONAL 
    352.     Figure 40. APAC PSORIASIS DRUG MARKET ANALYSIS 
    353.     Figure 41. CHINA PSORIASIS DRUG MARKET ANALYSIS BY MEDICATION TYPE 
    354.     Figure 42. CHINA PSORIASIS DRUG MARKET ANALYSIS BY ROUTE OF ADMINISTRATION 
    355.     Figure 43. CHINA PSORIASIS DRUG MARKET ANALYSIS BY DISEASE SEVERITY 
    356.     Figure 44. CHINA PSORIASIS DRUG MARKET ANALYSIS BY REGIONAL 
    357.     Figure 45. INDIA PSORIASIS DRUG MARKET ANALYSIS BY MEDICATION TYPE 
    358.     Figure 46. INDIA PSORIASIS DRUG MARKET ANALYSIS BY ROUTE OF ADMINISTRATION 
    359.     Figure 47. INDIA PSORIASIS DRUG MARKET ANALYSIS BY DISEASE SEVERITY 
    360.     Figure 48. INDIA PSORIASIS DRUG MARKET ANALYSIS BY REGIONAL 
    361.     Figure 49. JAPAN PSORIASIS DRUG MARKET ANALYSIS BY MEDICATION TYPE 
    362.     Figure 50. JAPAN PSORIASIS DRUG MARKET ANALYSIS BY ROUTE OF ADMINISTRATION 
    363.     Figure 51. JAPAN PSORIASIS DRUG MARKET ANALYSIS BY DISEASE SEVERITY 
    364.     Figure 52. JAPAN PSORIASIS DRUG MARKET ANALYSIS BY REGIONAL 
    365.     Figure 53. SOUTH KOREA PSORIASIS DRUG MARKET ANALYSIS BY MEDICATION TYPE 
    366.     Figure 54. SOUTH KOREA PSORIASIS DRUG MARKET ANALYSIS BY ROUTE OF ADMINISTRATION 
    367.     Figure 55. SOUTH KOREA PSORIASIS DRUG MARKET ANALYSIS BY DISEASE SEVERITY 
    368.     Figure 56. SOUTH KOREA PSORIASIS DRUG MARKET ANALYSIS BY REGIONAL 
    369.     Figure 57. MALAYSIA PSORIASIS DRUG MARKET ANALYSIS BY MEDICATION TYPE 
    370.     Figure 58. MALAYSIA PSORIASIS DRUG MARKET ANALYSIS BY ROUTE OF ADMINISTRATION 
    371.     Figure 59. MALAYSIA PSORIASIS DRUG MARKET ANALYSIS BY DISEASE SEVERITY 
    372.     Figure 60. MALAYSIA PSORIASIS DRUG MARKET ANALYSIS BY REGIONAL 
    373.     Figure 61. THAILAND PSORIASIS DRUG MARKET ANALYSIS BY MEDICATION TYPE 
    374.     Figure 62. THAILAND PSORIASIS DRUG MARKET ANALYSIS BY ROUTE OF ADMINISTRATION 
    375.     Figure 63. THAILAND PSORIASIS DRUG MARKET ANALYSIS BY DISEASE SEVERITY 
    376.     Figure 64. THAILAND PSORIASIS DRUG MARKET ANALYSIS BY REGIONAL 
    377.     Figure 65. INDONESIA PSORIASIS DRUG MARKET ANALYSIS BY MEDICATION TYPE 
    378.     Figure 66. INDONESIA PSORIASIS DRUG MARKET ANALYSIS BY ROUTE OF ADMINISTRATION 
    379.     Figure 67. INDONESIA PSORIASIS DRUG MARKET ANALYSIS BY DISEASE SEVERITY 
    380.     Figure 68. INDONESIA PSORIASIS DRUG MARKET ANALYSIS BY REGIONAL 
    381.     Figure 69. REST OF APAC PSORIASIS DRUG MARKET ANALYSIS BY MEDICATION TYPE 
    382.     Figure 70. REST OF APAC PSORIASIS DRUG MARKET ANALYSIS BY ROUTE OF ADMINISTRATION 
    383.     Figure 71. REST OF APAC PSORIASIS DRUG MARKET ANALYSIS BY DISEASE SEVERITY 
    384.     Figure 72. REST OF APAC PSORIASIS DRUG MARKET ANALYSIS BY REGIONAL 
    385.     Figure 73. SOUTH AMERICA PSORIASIS DRUG MARKET ANALYSIS 
    386.     Figure 74. BRAZIL PSORIASIS DRUG MARKET ANALYSIS BY MEDICATION TYPE 
    387.     Figure 75. BRAZIL PSORIASIS DRUG MARKET ANALYSIS BY ROUTE OF ADMINISTRATION 
    388.     Figure 76. BRAZIL PSORIASIS DRUG MARKET ANALYSIS BY DISEASE SEVERITY 
    389.     Figure 77. BRAZIL PSORIASIS DRUG MARKET ANALYSIS BY REGIONAL 
    390.     Figure 78. MEXICO PSORIASIS DRUG MARKET ANALYSIS BY MEDICATION TYPE 
    391.     Figure 79. MEXICO PSORIASIS DRUG MARKET ANALYSIS BY ROUTE OF ADMINISTRATION 
    392.     Figure 80. MEXICO PSORIASIS DRUG MARKET ANALYSIS BY DISEASE SEVERITY 
    393.     Figure 81. MEXICO PSORIASIS DRUG MARKET ANALYSIS BY REGIONAL 
    394.     Figure 82. ARGENTINA PSORIASIS DRUG MARKET ANALYSIS BY MEDICATION TYPE 
    395.     Figure 83. ARGENTINA PSORIASIS DRUG MARKET ANALYSIS BY ROUTE OF ADMINISTRATION 
    396.     Figure 84. ARGENTINA PSORIASIS DRUG MARKET ANALYSIS BY DISEASE SEVERITY 
    397.     Figure 85. ARGENTINA PSORIASIS DRUG MARKET ANALYSIS BY REGIONAL 
    398.     Figure 86. REST OF SOUTH AMERICA PSORIASIS DRUG MARKET ANALYSIS BY MEDICATION TYPE 
    399.     Figure 87. REST OF SOUTH AMERICA PSORIASIS DRUG MARKET ANALYSIS BY ROUTE OF ADMINISTRATION 
    400.     Figure 88. REST OF SOUTH AMERICA PSORIASIS DRUG MARKET ANALYSIS BY DISEASE SEVERITY 
    401.     Figure 89. REST OF SOUTH AMERICA PSORIASIS DRUG MARKET ANALYSIS BY REGIONAL 
    402.     Figure 90. MEA PSORIASIS DRUG MARKET ANALYSIS 
    403.     Figure 91. GCC COUNTRIES PSORIASIS DRUG MARKET ANALYSIS BY MEDICATION TYPE 
    404.     Figure 92. GCC COUNTRIES PSORIASIS DRUG MARKET ANALYSIS BY ROUTE OF ADMINISTRATION 
    405.     Figure 93. GCC COUNTRIES PSORIASIS DRUG MARKET ANALYSIS BY DISEASE SEVERITY 
    406.     Figure 94. GCC COUNTRIES PSORIASIS DRUG MARKET ANALYSIS BY REGIONAL 
    407.     Figure 95. SOUTH AFRICA PSORIASIS DRUG MARKET ANALYSIS BY MEDICATION TYPE 
    408.     Figure 96. SOUTH AFRICA PSORIASIS DRUG MARKET ANALYSIS BY ROUTE OF ADMINISTRATION 
    409.     Figure 97. SOUTH AFRICA PSORIASIS DRUG MARKET ANALYSIS BY DISEASE SEVERITY 
    410.     Figure 98. SOUTH AFRICA PSORIASIS DRUG MARKET ANALYSIS BY REGIONAL 
    411.     Figure 99. REST OF MEA PSORIASIS DRUG MARKET ANALYSIS BY MEDICATION TYPE 
    412.     Figure 100. REST OF MEA PSORIASIS DRUG MARKET ANALYSIS BY ROUTE OF ADMINISTRATION 
    413.     Figure 101. REST OF MEA PSORIASIS DRUG MARKET ANALYSIS BY DISEASE SEVERITY 
    414.     Figure 102. REST OF MEA PSORIASIS DRUG MARKET ANALYSIS BY REGIONAL 
    415.     Figure 103. KEY BUYING CRITERIA OF PSORIASIS DRUG MARKET 
    416.     Figure 104. RESEARCH PROCESS OF MRFR 
    417.     Figure 105. DRO ANALYSIS OF PSORIASIS DRUG MARKET 
    418.     Figure 106. DRIVERS IMPACT ANALYSIS: PSORIASIS DRUG MARKET 
    419.     Figure 107. RESTRAINTS IMPACT ANALYSIS: PSORIASIS DRUG MARKET 
    420.     Figure 108. SUPPLY / VALUE CHAIN: PSORIASIS DRUG MARKET 
    421.     Figure 109. PSORIASIS DRUG MARKET, BY MEDICATION TYPE, 2024 (% SHARE) 
    422.     Figure 110. PSORIASIS DRUG MARKET, BY MEDICATION TYPE, 2019 TO 2032 (USD Billions) 
    423.     Figure 111. PSORIASIS DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE) 
    424.     Figure 112. PSORIASIS DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019 TO 2032 (USD Billions) 
    425.     Figure 113. PSORIASIS DRUG MARKET, BY DISEASE SEVERITY, 2024 (% SHARE) 
    426.     Figure 114. PSORIASIS DRUG MARKET, BY DISEASE SEVERITY, 2019 TO 2032 (USD Billions) 
    427.     Figure 115. PSORIASIS DRUG MARKET, BY REGIONAL, 2024 (% SHARE) 
    428.     Figure 116. PSORIASIS DRUG MARKET, BY REGIONAL, 2019 TO 2032 (USD Billions) 
    429.     Figure 117. BENCHMARKING OF MAJOR COMPETITORS 

    Psoriasis Drug Market Segmentation

     

    Psoriasis Drug Market By Medication Type (USD Billion, 2019-2032)

    • Topical Treatments

    • Systemic Therapies

    • Biologics

     

     

    Psoriasis Drug Market By Route of Administration (USD Billion, 2019-2032)

    • Topical

    • Oral

    • Injectable

     

     

    Psoriasis Drug Market By Disease Severity (USD Billion, 2019-2032)

    • Mild to Moderate

    • Moderate to Severe

    • Severe

     

     

    Psoriasis Drug Market By Regional (USD Billion, 2019-2032)

    • North America

    • Europe

    • South America

    • Asia Pacific

    • Middle East and Africa

     

    Psoriasis Drug Market Regional Outlook (USD Billion, 2019-2032)

     

     

    • North America Outlook (USD Billion, 2019-2032)

      • North America Psoriasis Drug Market by Medication Type

        • Topical Treatments
        • Systemic Therapies
        • Biologics

      • North America Psoriasis Drug Market by Route of Administration Type

        • Topical
        • Oral
        • Injectable

      • North America Psoriasis Drug Market by Disease Severity Type

        • Mild to Moderate
        • Moderate to Severe
        • Severe

      • North America Psoriasis Drug Market by Regional Type

        • US
        • Canada
      • US Outlook (USD Billion, 2019-2032)

      • US Psoriasis Drug Market by Medication Type

        • Topical Treatments
        • Systemic Therapies
        • Biologics

      • US Psoriasis Drug Market by Route of Administration Type

        • Topical
        • Oral
        • Injectable

      • US Psoriasis Drug Market by Disease Severity Type

        • Mild to Moderate
        • Moderate to Severe
        • Severe
      • CANADA Outlook (USD Billion, 2019-2032)

      • CANADA Psoriasis Drug Market by Medication Type

        • Topical Treatments
        • Systemic Therapies
        • Biologics

      • CANADA Psoriasis Drug Market by Route of Administration Type

        • Topical
        • Oral
        • Injectable

      • CANADA Psoriasis Drug Market by Disease Severity Type

        • Mild to Moderate
        • Moderate to Severe
        • Severe

    • Europe Outlook (USD Billion, 2019-2032)

      • Europe Psoriasis Drug Market by Medication Type

        • Topical Treatments
        • Systemic Therapies
        • Biologics

      • Europe Psoriasis Drug Market by Route of Administration Type

        • Topical
        • Oral
        • Injectable

      • Europe Psoriasis Drug Market by Disease Severity Type

        • Mild to Moderate
        • Moderate to Severe
        • Severe

      • Europe Psoriasis Drug Market by Regional Type

        • Germany
        • UK
        • France
        • Russia
        • Italy
        • Spain
        • Rest of Europe
      • GERMANY Outlook (USD Billion, 2019-2032)

      • GERMANY Psoriasis Drug Market by Medication Type

        • Topical Treatments
        • Systemic Therapies
        • Biologics

      • GERMANY Psoriasis Drug Market by Route of Administration Type

        • Topical
        • Oral
        • Injectable

      • GERMANY Psoriasis Drug Market by Disease Severity Type

        • Mild to Moderate
        • Moderate to Severe
        • Severe
      • UK Outlook (USD Billion, 2019-2032)

      • UK Psoriasis Drug Market by Medication Type

        • Topical Treatments
        • Systemic Therapies
        • Biologics

      • UK Psoriasis Drug Market by Route of Administration Type

        • Topical
        • Oral
        • Injectable

      • UK Psoriasis Drug Market by Disease Severity Type

        • Mild to Moderate
        • Moderate to Severe
        • Severe
      • FRANCE Outlook (USD Billion, 2019-2032)

      • FRANCE Psoriasis Drug Market by Medication Type

        • Topical Treatments
        • Systemic Therapies
        • Biologics

      • FRANCE Psoriasis Drug Market by Route of Administration Type

        • Topical
        • Oral
        • Injectable

      • FRANCE Psoriasis Drug Market by Disease Severity Type

        • Mild to Moderate
        • Moderate to Severe
        • Severe
      • RUSSIA Outlook (USD Billion, 2019-2032)

      • RUSSIA Psoriasis Drug Market by Medication Type

        • Topical Treatments
        • Systemic Therapies
        • Biologics

      • RUSSIA Psoriasis Drug Market by Route of Administration Type

        • Topical
        • Oral
        • Injectable

      • RUSSIA Psoriasis Drug Market by Disease Severity Type

        • Mild to Moderate
        • Moderate to Severe
        • Severe
      • ITALY Outlook (USD Billion, 2019-2032)

      • ITALY Psoriasis Drug Market by Medication Type

        • Topical Treatments
        • Systemic Therapies
        • Biologics

      • ITALY Psoriasis Drug Market by Route of Administration Type

        • Topical
        • Oral
        • Injectable

      • ITALY Psoriasis Drug Market by Disease Severity Type

        • Mild to Moderate
        • Moderate to Severe
        • Severe
      • SPAIN Outlook (USD Billion, 2019-2032)

      • SPAIN Psoriasis Drug Market by Medication Type

        • Topical Treatments
        • Systemic Therapies
        • Biologics

      • SPAIN Psoriasis Drug Market by Route of Administration Type

        • Topical
        • Oral
        • Injectable

      • SPAIN Psoriasis Drug Market by Disease Severity Type

        • Mild to Moderate
        • Moderate to Severe
        • Severe
      • REST OF EUROPE Outlook (USD Billion, 2019-2032)

      • REST OF EUROPE Psoriasis Drug Market by Medication Type

        • Topical Treatments
        • Systemic Therapies
        • Biologics

      • REST OF EUROPE Psoriasis Drug Market by Route of Administration Type

        • Topical
        • Oral
        • Injectable

      • REST OF EUROPE Psoriasis Drug Market by Disease Severity Type

        • Mild to Moderate
        • Moderate to Severe
        • Severe

    • APAC Outlook (USD Billion, 2019-2032)

      • APAC Psoriasis Drug Market by Medication Type

        • Topical Treatments
        • Systemic Therapies
        • Biologics

      • APAC Psoriasis Drug Market by Route of Administration Type

        • Topical
        • Oral
        • Injectable

      • APAC Psoriasis Drug Market by Disease Severity Type

        • Mild to Moderate
        • Moderate to Severe
        • Severe

      • APAC Psoriasis Drug Market by Regional Type

        • China
        • India
        • Japan
        • South Korea
        • Malaysia
        • Thailand
        • Indonesia
        • Rest of APAC
      • CHINA Outlook (USD Billion, 2019-2032)

      • CHINA Psoriasis Drug Market by Medication Type

        • Topical Treatments
        • Systemic Therapies
        • Biologics

      • CHINA Psoriasis Drug Market by Route of Administration Type

        • Topical
        • Oral
        • Injectable

      • CHINA Psoriasis Drug Market by Disease Severity Type

        • Mild to Moderate
        • Moderate to Severe
        • Severe
      • INDIA Outlook (USD Billion, 2019-2032)

      • INDIA Psoriasis Drug Market by Medication Type

        • Topical Treatments
        • Systemic Therapies
        • Biologics

      • INDIA Psoriasis Drug Market by Route of Administration Type

        • Topical
        • Oral
        • Injectable

      • INDIA Psoriasis Drug Market by Disease Severity Type

        • Mild to Moderate
        • Moderate to Severe
        • Severe
      • JAPAN Outlook (USD Billion, 2019-2032)

      • JAPAN Psoriasis Drug Market by Medication Type

        • Topical Treatments
        • Systemic Therapies
        • Biologics

      • JAPAN Psoriasis Drug Market by Route of Administration Type

        • Topical
        • Oral
        • Injectable

      • JAPAN Psoriasis Drug Market by Disease Severity Type

        • Mild to Moderate
        • Moderate to Severe
        • Severe
      • SOUTH KOREA Outlook (USD Billion, 2019-2032)

      • SOUTH KOREA Psoriasis Drug Market by Medication Type

        • Topical Treatments
        • Systemic Therapies
        • Biologics

      • SOUTH KOREA Psoriasis Drug Market by Route of Administration Type

        • Topical
        • Oral
        • Injectable

      • SOUTH KOREA Psoriasis Drug Market by Disease Severity Type

        • Mild to Moderate
        • Moderate to Severe
        • Severe
      • MALAYSIA Outlook (USD Billion, 2019-2032)

      • MALAYSIA Psoriasis Drug Market by Medication Type

        • Topical Treatments
        • Systemic Therapies
        • Biologics

      • MALAYSIA Psoriasis Drug Market by Route of Administration Type

        • Topical
        • Oral
        • Injectable

      • MALAYSIA Psoriasis Drug Market by Disease Severity Type

        • Mild to Moderate
        • Moderate to Severe
        • Severe
      • THAILAND Outlook (USD Billion, 2019-2032)

      • THAILAND Psoriasis Drug Market by Medication Type

        • Topical Treatments
        • Systemic Therapies
        • Biologics

      • THAILAND Psoriasis Drug Market by Route of Administration Type

        • Topical
        • Oral
        • Injectable

      • THAILAND Psoriasis Drug Market by Disease Severity Type

        • Mild to Moderate
        • Moderate to Severe
        • Severe
      • INDONESIA Outlook (USD Billion, 2019-2032)

      • INDONESIA Psoriasis Drug Market by Medication Type

        • Topical Treatments
        • Systemic Therapies
        • Biologics

      • INDONESIA Psoriasis Drug Market by Route of Administration Type

        • Topical
        • Oral
        • Injectable

      • INDONESIA Psoriasis Drug Market by Disease Severity Type

        • Mild to Moderate
        • Moderate to Severe
        • Severe
      • REST OF APAC Outlook (USD Billion, 2019-2032)

      • REST OF APAC Psoriasis Drug Market by Medication Type

        • Topical Treatments
        • Systemic Therapies
        • Biologics

      • REST OF APAC Psoriasis Drug Market by Route of Administration Type

        • Topical
        • Oral
        • Injectable

      • REST OF APAC Psoriasis Drug Market by Disease Severity Type

        • Mild to Moderate
        • Moderate to Severe
        • Severe

    • South America Outlook (USD Billion, 2019-2032)

      • South America Psoriasis Drug Market by Medication Type

        • Topical Treatments
        • Systemic Therapies
        • Biologics

      • South America Psoriasis Drug Market by Route of Administration Type

        • Topical
        • Oral
        • Injectable

      • South America Psoriasis Drug Market by Disease Severity Type

        • Mild to Moderate
        • Moderate to Severe
        • Severe

      • South America Psoriasis Drug Market by Regional Type

        • Brazil
        • Mexico
        • Argentina
        • Rest of South America
      • BRAZIL Outlook (USD Billion, 2019-2032)

      • BRAZIL Psoriasis Drug Market by Medication Type

        • Topical Treatments
        • Systemic Therapies
        • Biologics

      • BRAZIL Psoriasis Drug Market by Route of Administration Type

        • Topical
        • Oral
        • Injectable

      • BRAZIL Psoriasis Drug Market by Disease Severity Type

        • Mild to Moderate
        • Moderate to Severe
        • Severe
      • MEXICO Outlook (USD Billion, 2019-2032)

      • MEXICO Psoriasis Drug Market by Medication Type

        • Topical Treatments
        • Systemic Therapies
        • Biologics

      • MEXICO Psoriasis Drug Market by Route of Administration Type

        • Topical
        • Oral
        • Injectable

      • MEXICO Psoriasis Drug Market by Disease Severity Type

        • Mild to Moderate
        • Moderate to Severe
        • Severe
      • ARGENTINA Outlook (USD Billion, 2019-2032)

      • ARGENTINA Psoriasis Drug Market by Medication Type

        • Topical Treatments
        • Systemic Therapies
        • Biologics

      • ARGENTINA Psoriasis Drug Market by Route of Administration Type

        • Topical
        • Oral
        • Injectable

      • ARGENTINA Psoriasis Drug Market by Disease Severity Type

        • Mild to Moderate
        • Moderate to Severe
        • Severe
      • REST OF SOUTH AMERICA Outlook (USD Billion, 2019-2032)

      • REST OF SOUTH AMERICA Psoriasis Drug Market by Medication Type

        • Topical Treatments
        • Systemic Therapies
        • Biologics

      • REST OF SOUTH AMERICA Psoriasis Drug Market by Route of Administration Type

        • Topical
        • Oral
        • Injectable

      • REST OF SOUTH AMERICA Psoriasis Drug Market by Disease Severity Type

        • Mild to Moderate
        • Moderate to Severe
        • Severe

    • MEA Outlook (USD Billion, 2019-2032)

      • MEA Psoriasis Drug Market by Medication Type

        • Topical Treatments
        • Systemic Therapies
        • Biologics

      • MEA Psoriasis Drug Market by Route of Administration Type

        • Topical
        • Oral
        • Injectable

      • MEA Psoriasis Drug Market by Disease Severity Type

        • Mild to Moderate
        • Moderate to Severe
        • Severe

      • MEA Psoriasis Drug Market by Regional Type

        • GCC Countries
        • South Africa
        • Rest of MEA
      • GCC COUNTRIES Outlook (USD Billion, 2019-2032)

      • GCC COUNTRIES Psoriasis Drug Market by Medication Type

        • Topical Treatments
        • Systemic Therapies
        • Biologics

      • GCC COUNTRIES Psoriasis Drug Market by Route of Administration Type

        • Topical
        • Oral
        • Injectable

      • GCC COUNTRIES Psoriasis Drug Market by Disease Severity Type

        • Mild to Moderate
        • Moderate to Severe
        • Severe
      • SOUTH AFRICA Outlook (USD Billion, 2019-2032)

      • SOUTH AFRICA Psoriasis Drug Market by Medication Type

        • Topical Treatments
        • Systemic Therapies
        • Biologics

      • SOUTH AFRICA Psoriasis Drug Market by Route of Administration Type

        • Topical
        • Oral
        • Injectable

      • SOUTH AFRICA Psoriasis Drug Market by Disease Severity Type

        • Mild to Moderate
        • Moderate to Severe
        • Severe
      • REST OF MEA Outlook (USD Billion, 2019-2032)

      • REST OF MEA Psoriasis Drug Market by Medication Type

        • Topical Treatments
        • Systemic Therapies
        • Biologics

      • REST OF MEA Psoriasis Drug Market by Route of Administration Type

        • Topical
        • Oral
        • Injectable

      • REST OF MEA Psoriasis Drug Market by Disease Severity Type

        • Mild to Moderate
        • Moderate to Severe
        • Severe

     

     

     

    Report Infographic
    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Related Reports

    No regional reports available for this market.

    No country-specific reports available for this market.

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne Founder
    Case Study

    Chemicals and Materials

    Global Magnesium Sulfate Market – Forecast till 2027